BIOFERMIN PHARMACEUTICAL CO.,LTD.
ビオフェルミン製薬株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4517
No filings in 18+ monthsFY2020 (Mar 2021) · J-GAAP · parent-only (non-consolidated) Source: filing S100LLTI
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2020 (Mar 2021) runs Apr 1, 2020 – Mar 31, 2021.
| Gross margin | 58.4% |
|---|---|
| Operating margin | 19.0% |
| Net margin | 14.3% |
| Return on equity | 5.2%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 4.7% |
| Revenue growth (YoY) | -9.3% |
| EPS (basic) | ¥129.45 |
| EPS growth (YoY) | -30.9% |
| Current ratio | 10.34x |
| Equity ratio | 91.1% |
| Book value / share | ¥2,541.33 |
| Free cash flow | −¥2.7B |